Venlafaxine for major depression: More evidence that risks outweigh benefits for most patients?

British Medical Journal

Volumn 334, Issue 7587, 2007, Pages 215-216

  Cipriani, Andrea ^a   Geddes, John R ^b   Barbui, Corrado ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY OF OXFORD   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CITALOPRAM; DOSULEPIN; FLUOXETINE; LITHIUM; VENLAFAXINE;

CARDIOTOXICITY; CLINICAL TRIAL; DEPRESSION; DRUG EFFICACY; DRUG WITHDRAWAL; EDITORIAL; HUMAN; MAJOR DEPRESSION; PATIENT COMPLIANCE; PATIENT SELECTION; PRACTICE GUIDELINE; PRESCRIPTION; PRIMARY MEDICAL CARE; PRIORITY JOURNAL; RISK FACTOR; SUICIDAL IDEATION; SUICIDE; SUICIDE ATTEMPT; TREATMENT OUTCOME;

ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER, MAJOR; HUMANS;

EID: 33846859566     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.39098.457720.BE     Document Type: Editorial

References (12)

1. Rubino A, Roskell N, Tennis P, Mines D, Weich S, Andrews E. Risk of suicide during treatment with venlafaxine, citalopram, fluoxetine, and dothiepin: retrospective cohort study. BMJ 2007;334: doi: 10.1136/bmj.39041.445104.BE.
2. Smith D, Dempster C, Glanville J, Freemantle N, Anderson I. Efficacy and tolerability of venlafaxine compared with selective serotonin reuptake inhibitors and other antidepressants: a meta-analysis. Br J Psychiatry 2002;180:396-404.
3. Hansen RA, Gartlehner G, Lohr KN, Gaynes BN, Carey TS. Efficacy and safety of second-generation antidepressants in the treatment of major depressive disorder. Ann Intern Med 2005;143:415-26.
4. Gartlehner G, Hansen RA, Carey TS, Lohr KN, Gaynes BN, Randolph LC. Discontinuation rates for selective serotonin reuptake inhibitors and other second-generation antidepressants in outpatients with major depressive disorder: a systematic review and meta-analysis. Int Clin Psychopharmacol 2005;20:59-69.
5. Jick H, Kaye JA, Jick SS. Antidepressants and the risk of suicidal behaviors. JAMA 2004;292:235-40.
6. Martinez C, Rietbrock S, Wise L, Ashby D, Chick J, Moseley J, et al. Antidepressant treatment and the risk of fatal and non-fatal self harm in first episode depression: nested case-control study. BMJ 2005;330:389-93.
7. Cipriani A, Pretty H, Hawton K, Geddes JR. Lithium in the prevention of suicidal behavior and all-cause mortality in patients with mood disorders: a systematic review of randomized trials. Am J Psychiatry 2005;162:1805-19.
8. Tiihonen J, Lonnqvist J, Wahlbeck K, Klaukka T, Tanskanen A, Haukka J. Antidepressants and the risk of suicide, attempted suicide, and overall mortality in a nationwide cohort. Arch Gen Psychiatry 2006;63:1358-67.
9. Licino J, Wong M. Depression, antidepressants and suicidality: a critical appraisal. Nat Rev Drug Disc 2005;4:165-71.
10. Cipriani A, Barbui C, Geddes JR. Suicide, depression, and antidepressants. BMJ 2005;330:373-4.
11. Hammad TA, Laughren T, Racoosin J. Suicidality in pediatric patients treated with antidepressant drugs. Arch Gen Psychiatry 2006;63:332-9.
12. Gunnell D, Saperia J, Ashby D. Selective serotonin reuptake inhibitors (SSRIs) and suicide in adults: meta-analysis of drug company data from placebo controlled, randomised controlled trials submitted to the MHRA's safety review. BMJ 2005;330:385-8.